Biochemical markers and assessment of cardiotoxicity during preparative regimen and hematopoietic cell transplantation in acute leukemia

Experimental Oncology

Volumn 29, Issue 3, 2007, Pages 243-247

  Horacek, J M ^a,b   Pudil, R ^a   Tichy, M ^a,b   Jebavy, L ^a,b   Zak, P ^a   Slovacek, L ^a,b   Maly, J ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY OF DEFENCE   (Czech Republic)

Author keywords

Acute leukemia; Biochemical markers; Cardiotoxicity; Transplantation

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BUSULFAN; CREATINE KINASE MB; CYCLOPHOSPHAMIDE; DAUNORUBICIN; IDARUBICIN; MITOXANTRONE; TROPONIN T;

ACUTE LEUKEMIA; ADULT; ARTICLE; CARDIOTOXICITY; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; WHOLE BODY RADIATION;

ACUTE DISEASE; ADULT; ANTHRACYCLINES; BIOLOGICAL MARKERS; CREATINE KINASE, MB FORM; ECHOCARDIOGRAPHY; FEMALE; HEART DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; MALE; MYELOABLATIVE AGONISTS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; TROPONIN T;

EID: 36749091179     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996; 125: 47-58.
2. Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J. Cardiotoxicity associated with high dose cyclophosphamide therapy. Arch Intern Med 1981; 141: 758-63.
3. Goldberg MA, Antin JH, Guinan EC, Rappeport JM. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood 1986; 68: 1114-8.
4. Morandi P, Ruffini PA, Benvenuto GM, Raimondi R, Fosser V. Cardiac toxicity of high-dose chemotherapy. Bone Marrow Transplant 2005; 35: 323-34.
5. Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, Durand JB, Gibbs H, Zafarmand AA, Ewer MS. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis and management. Circulation 2004; 109: 3122-31.
6. Ganz WI, Sridhar KS, Ganz SS, Gonzalez R, Chakko S, Serafini A. Review of tests for monitoring doxorubicin-induced cardiomyopathy. Oncology 1996; 53: 461-70.
7. Meinardi MT, van der Graaf WT, van Veldhuisen DJ, Gietema JA, de Vries EG, Sleijfer DT. Detection of anthracycline-induced cardiotoxicity. Cancer Treat Rev 1999; 25: 237-47.
8. Elbl L, Vasova I, Kral Z, Tomaskova I, Smardova L, Wagnerova B, Jedlicka F, Vorlicek J. Evaluation of acute and early cardiotoxicity in survivors of Hodgkin's disease treated with ABVD or BEACOPP regimens. J Chemother 2006; 18: 199-208.
9. Sparano JA, Brown DL, Wolff AC. Predicting cancer therapy-induced cardiotoxicity. The role of troponins and other markers. Drug Saf 2002; 25: 301-11.
10. Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, Ogawa H, Okumura K, Mukoyama M, Nakao K. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994; 90: 195-203.
11. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001; 22: 1527-60.
12. Cowie MR, Jourdain P, Maisel A, Dahlstrom U, Follath F, Isnard R, Luchner A, McDonagh T, Mair J, Nieminen M, Francis G. Clinical application of B-type natriuretic peptide (BNP) testing. Eur Heart J 2003; 24: 1710-8.
13. De Lemos JA, Morrow DA. Combining natriuretic peptides and necrosis markers in the assessment of acute coronary syndromes. Rev Cardiovasc Med 2003; 4 (Suppl 4): 37-46.
14. Cardinale D, Sandri MT, Martinoni A, Tricca A, Civelli M, Lamantia G, Cinieri S, Martinelli G, Cipolla CM, Fiorentini C. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000; 36: 517-22.
15. Sandri MT, Cardinale D, Zorzino L, Passerini R, Lentati P, Martinoni A, Martinelli G, Cipolla CM. Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. Clin Chem 2003; 49: 248-52.
16. Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, Civelli M, Peccatori F, Martinelli G, Fiorentini C, Cipolla CM. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004; 109: 2749-54.
17. Snowden JA, Hill GR, Hunt P, Carnoutsos S, Spearing RL, Espiner E, Hart DN. Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide. Bone Marrow Transplant 2000; 26: 309-13.
18. Niwa N, Watanabe E, Hamaguchi M, Kodera Y, Miyazaki H, Kodama I, Ohono M. Early and late elevation of plasma atrial and brain natriuretic peptides in patients after bone marrow transplantation. Ann Hematol 2001; 80: 460-5.
19. Sandri MT, Salvatici M, Cardinale D, Zorzino L, Passerini R, Lentati P, Leon M, Civelli M, Martinelli G, Cipolla CM. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem 2005; 51: 1405-10.
20. Hess G, Runkel S, Zdunek D, Hitzler WE. N-terminal pro-brain natriuretic peptide (NT-proBNP) in healthy blood donors and in patients from general practitioners with and without a diagnosis of cardiac disease. Clin Lab 2005; 51: 167-72.
21. Horacek JM, Pudil R, Jebavy L, Strasová A, Praus R, Zák P, Malý J. The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia. Neoplasma 2005; 52: 430-4.
22. Adamcova M, Sterba M, Simunek T, Potacova A, Popelova O, Mazurova Y, Gersl V. Troponin as a marker of myocardiac damage in drug-induced cardiotoxicity. Expert Opin Drug Saf 2005; 4: 457-72.
23. Panteghini M. The measurement of cardiac markers: where should we focus? Am J Clin Pathol 2002; 118: 354-61.
24. Auner HW, Tinchon C, Brezinschek RI, Eibl M, Sormann S, Maizen C, Linkesch W, Schmon-Kampel R, Quehenberger F, Tiran A, Sill H. Monitoring of cardiac function by serum cardiac troponin T levels, ventricular repolarization indices, and echocardiography after conditioning with fractionated total body irradiation and high-dose cyclophosphamide. Eur J Haematol 2002; 69: 1-6.
25. Benvenuto GM, La Vecchia L, Morandi P, Ruffini P, Mezzena G. Assessment of cardiotoxicity of high dose cyclophosphamide with electrocardiographic, echocardiographic, and troponin I monitoring in patients with breast tumors. Ital Heart J Suppl 2000; 1: 1457-63.
26. Petersen FB, Bearman SI. Preparative regimens and their toxicity. In: Forman SJ, Blume KG, Thomas ED, eds. Bone marrow transplantation. Boston: Blackwell Scientific Publications, 1994: 79-83.